Instil Bio, Inc.

$6.00 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Instil Bio, Inc.

Instil Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a cell therapy pipeline of autologous tumor-infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer. TIL therapies leverage platform for TIL manufacturing has been designed for the scalability, logistics, and accessibility of TIL therapy. It is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. It is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform. ITIL-168 is an autologous TIL therapy that it is initially developed for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Its pipeline also includes ITIL-306, its CoStAR-TIL product candidate.

Stock Analysis

last close $6
1-mo return -26.3%
3-mo return -44.4%
avg daily vol. 648.25T
52-week high 23.68
52-week low 4.34
market cap. $940M
forward pe -
annual div. -
roe -32%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 91.8%
baraka

Subscribe now for daily local and international financial news

Subscribe